Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae – a prospective cohort study

Table 1 Baseline characteristics of 23 patients with Chlamydia trachomatis and Neisseria gonorrhoeae coinfection at inclusion

Characteristics	Total N (%)^a	Urethra N (%)^a	Rectum N (%)^a	Endocervix N (%)^a	P
Total	23	7 (30.4)	7 (30.4)	9 (39.1)
Gender
Male	14 (60.9)	7 (100.0)	7 (100.0)	0 (0.0)
Female	9 (39.1)	0 (0.0)	0 (0.0)	9 (100.0)
Median age, in years (IQR)	24 (20–35)	29 (24–35)	40 (24–44)	20 (19–23)	0.003
Ethnicity					1.00
Dutch	11 (47.8)	3 (42.9)	4 (57.1)	4 (44.4)
Non-Dutch	12 (52.2)	4 (57.1)	3 (42.9)	5 (55.6)
Sexual risk group
MSM	10 (43.5)	3 (42.9)	7 (100.0)	0 (0.0)
Hetero male	4 (17.4)	4 (57.1)	0 (0.0)	0 (0.0)
Female	9 (39.1)	0 (0.0)	0 (0.0)	9 (100.0)
HIV positive	5 (21.7)	1 (14.3)	4 (57.1)	0 (0.0)	0.02
Using cART	4 (80.0)	0 (0.0)	4 (100.0)	-	0.20
CD₄⁺ cell count (cells/mm³)					1.00
350–499	1 (20.0)	0 (0.0)	1 (25.0)	-
≥ 500	4 (80.0)	1 (100.0)	3 (75.0)	-
Previous chlamydia episode	12 (52.2)	3 (42.9)	4 (57.1)	5 (55.6)	1.00
Chlamydia in preceding 6 months	3 (13.0)	0 (0.0)	1 (14.3)	2 (22.2)	0.75
Symptoms or signs at examination^b,c	13 (56.5)	6 (85.7)	3 (42.9)	4 (44.4)	0.23
Median time to inclusion, days (IQR)	8 (0–12)	0 (0–0)	10 (7–13)	9 (8–12)	0.003
Treatment at inclusion^d					0.001
Ceftriaxone + azithromycin	16 (69.6)	7 (100.0)	1 (14.3)	8 (88.9)
Ceftriaxone + doxycycline	7 (30.4)	0 (0.0)	6 (85.7)	1 (11.1)

IQR interquartile range, MSM men who have sex with men, HIV human immunodeficiency virus, cART combination antiretroviral therapy
^aUnless otherwise indicated
^bSymptoms included: discharge, itch, burning, frequent or painful urination, bleeding, abdominal pain, pain during sex, anal cramps or pain, and changed defecation
^cSigns included: red urethra, discharge, bleeding, fragile mucosa, swelling or anal ulcerations
^d1 patient was negative for Chlamydia trachomatis at the initial visit and therefore received ceftriaxone mono-therapy. The test at inclusion was positive and doxycycline was started 6 days after inclusion; therefore the start of the study for the C. trachomatis analysis in this patient was day 6, and the treatment was ceftriaxone + doxycycline

ISSN: 1471-2334